Gene Biotherapeutics, Inc.
DelistedCIK 772320fmd_0VA08HMEHD9Z63QH2626Q5A9QZManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2010 to Dec 31, 2020, 43 periods
Latest annual · FY2020
Millions- Operating income
- (1)
- Net income
- (1)
- Free cash flow
- (1)
Latest quarter · Q4 FY2020
Millions- Operating income
- (1)
- Net income
- (0)
- Free cash flow
- (0)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2015 to FY2020
- n/m
Gene Biotherapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2020 | FY2019 | Change | Source |
|---|---|---|---|---|
| Operating income | -$1.3 million | -$837,002 | 10-K 2022-03-30 · proof | |
| Net income | -$517,897 | $866,675 | -159.8% | 10-K 2022-03-30 · proof |
| Cash from operating activities | -$1.1 million | -$137,162 | 10-K 2022-03-30 · proof | |
| Free cash flow | -$1.1 million | 10-K 2022-03-30 · proof | ||
| Total assets | $566,982 | $35,435 | +1,500.1% | 10-K 2022-03-30 · proof |
| Total liabilities | $5.1 million | $4.9 million | +5.1% | 10-K 2022-03-30 · proof |
| Cash and cash equivalents | $386,027 | $400 | +96,406.8% | 10-K 2022-03-30 · proof |
- What was Gene Biotherapeutics, Inc.'s operating income in fiscal 2020?
- Gene Biotherapeutics, Inc. reported operating income of -$1.3 million for fiscal 2020 (the year ended Dec 31, 2020), against -$837,002 the year before. Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
- What was Gene Biotherapeutics, Inc.'s net income in fiscal 2020?
- Gene Biotherapeutics, Inc. reported net income of -$517,897 for fiscal 2020 (the year ended Dec 31, 2020), against $866,675 the year before (-159.8%). Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
- What was Gene Biotherapeutics, Inc.'s cash from operating activities in fiscal 2020?
- Gene Biotherapeutics, Inc. reported cash from operating activities of -$1.1 million for fiscal 2020 (the year ended Dec 31, 2020), against -$137,162 the year before. Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
- What was Gene Biotherapeutics, Inc.'s free cash flow in fiscal 2020?
- Gene Biotherapeutics, Inc. reported free cash flow of -$1.1 million for fiscal 2020 (the year ended Dec 31, 2020). Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
- What are Gene Biotherapeutics, Inc.'s total assets?
- As of Dec 31, 2020, Gene Biotherapeutics, Inc. reported total assets of $566,982, against $35,435 a year earlier (+1,500.1%). Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
- What are Gene Biotherapeutics, Inc.'s total liabilities?
- As of Dec 31, 2020, Gene Biotherapeutics, Inc. reported total liabilities of $5.1 million, against $4.9 million a year earlier (+5.1%). Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
- What are Gene Biotherapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2020, Gene Biotherapeutics, Inc. reported cash and cash equivalents of $386,027, against $400 a year earlier (+96,406.8%). Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:772320&period_type=annual&limit=5"Information only, not investment advice.